Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

 
• By Neena Brizmohun
  
Alzheimer's patient
Donanemab was shown to significantly slow cognitive and functional decline in people with early symptomatic Alzheimer's disease • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography